WuXi AppTec, the mainland’s leading biotechnology firm which privatised in New York two years ago, has been given the green light to relist on the A-share market via an initial public offering (IPO) in Shanghai, just seven weeks after filing its application.
The listing is expected to raise more than 5.7 billion yuan (US$907.5 million), which the firm will use to expand research facilities and build new plants.
